Literature DB >> 12658548

Indocyanine green-mediated photothrombosis as a new technique of treatment for persistent central serous chorioretinopathy.

Rogério A Costa1, Luciana Scapucin, Nilva S Moraes, Daniela Calucci, Luiz A Melo, José A Cardillo, Michel E Farah.   

Abstract

PURPOSE: To evaluate the potential benefit and complications of indocyanine green-mediated photothrombosis (IMP) in the management of patients with persistent central serous chorioretinopathy (CSC).
METHODS: Interventional noncomparative case series. Eleven patients with CSC presenting with persistent subretinal fluid in optical coherence tomography (OCT) four months after presentation and decrease in visual acuity (VA) were submitted to a single IMP session with 2 mg/kg body weight ICG and application of 5.6 W/cm(2) light at 810 nm. A continuous follow-up was provided with best-corrected ETDRS VA assessment, and angiographic and OCT documentation 72 hours before and at 2 days, 1 and 2 weeks, 1, 3, 6, and 12 months after treatment.
RESULTS: Pretreatment VA levels ranged from 20/32 - 1 to 20/100 (mean, 20/63 + 2 [logMAR equivalent, 0.460 +/- 0.155]); post treatment levels ranged from 20/25 - 2 to 20/20 (mean, 20/20 - 2 [logMAR equivalent, 0.038 +/- 0.048]). Ten out of eleven patients presented with VA levels of >/=20/25 2 weeks after treatment; the mean logMAR VA change of 0.345 at that time was statistically significant (p < 0.05, Friedman test). OCT disclosed resolution of persistent subretinal fluid in all eyes. No recurrence was observed after 12 months of follow-up. Complications included transient retinal whitening in two patients, and associated occlusion of retinal capillaries in one.
CONCLUSIONS: Photothrombosis using low-intensity 810 nm light to direct laser energy continuously at the active leakage sites after intravenous ICG infusion induced rapid VA recovery in patients with persistent CSC; accordingly, restoration of the macular architecture was evidenced on OCT, and no recurrence was noted 12 months after IMP.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12658548     DOI: 10.1076/ceyr.25.5.287.13496

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  8 in total

1.  Indocyanine green-mediated photothrombosis with intravitreal triamcinolone acetonide for subfoveal choroidal neovascularization in age-related macular degeneration.

Authors:  J Fernando Arevalo; Reinaldo A Garcia; Aristides J Mendoza
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-05-20       Impact factor: 3.117

2.  Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments.

Authors:  Fabio Bom Aggio; Michel Eid Farah; Wagner Camilo Silva; Gustavo Barreto Melo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-02       Impact factor: 3.117

3.  Evaluation of central serous retinopathy with en face optical coherence tomography.

Authors:  M E J van Velthoven; F D Verbraak; P M Garcia; R O Schlingemann; R B Rosen; M D de Smet
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

4.  Indocyanine green mediated photothrombosis for the management of predominantly classic choroidal neovascularisation caused by age related macular degeneration.

Authors:  M E Farah; J A Cardillo; A C Luzardo; D Calucci; G A Williams; R A Costa
Journal:  Br J Ophthalmol       Date:  2004-08       Impact factor: 4.638

5.  Indocyanine green enhanced subthreshold diode-laser micropulse photocoagulation treatment of chronic central serous chorioretinopathy.

Authors:  F Ricci; F Missiroli; F Regine; M Grossi; G Dorin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-12-17       Impact factor: 3.117

6.  Indocyanine-green-mediated photothrombosis (IMP) with intravitreal triamcinolone acetonide for macular edema secondary to group 2A idiopathic parafoveal telangiectasis without choroidal neovascularization: a pilot study.

Authors:  J Fernando Arevalo; Juan G Sanchez; Reinaldo A Garcia; Lihteh Wu; Maria H Berrocal; Francisco J Rodriguez; Alvaro Rodríguez; Liliana Andrea Novoa; Rafael Garcia-Amaris
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-07-10       Impact factor: 3.117

7.  Indocyanine green mediated photothrombosis and high dose intravitreal bevacizumab as adjuvant therapy for isolated choroidal metastasis from breast cancer.

Authors:  J Fernando Arevalo; Juan V Espinoza
Journal:  J Ophthalmic Vis Res       Date:  2012-10

8.  Erythrocyte-derived photo-theranostic agents: hybrid nano-vesicles containing indocyanine green for near infrared imaging and therapeutic applications.

Authors:  Baharak Bahmani; Danielle Bacon; Bahman Anvari
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.